Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12234277
Hydrophobic interaction chromatography for viral clearance
granted -
US 12233081
Hygromycin a compounds and methods of treating spirochete diseases
granted -
US 12233092
MSC-NTF specific exosomes and use thereof
granted -
US 12233124
Recombinant metapneumovirus f proteins and their use
granted -
US 12234230
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
granted -
US 12233105
Methods for storing and warming purified corticotropin compositions
granted -
US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
granted -
US 12233150
Oral care compositions comprising star-shaped polymers
granted -
US 12234300
Conjugated hepcidin mimetics
granted -
US 12234302
Chitosan derivatives and methods for preparing the same
granted -
US 12234460
Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
granted -
US 12233080
Lipotechoic acid for immune modulation
granted -
US 12233087
Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233104
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
granted -
US 12233090
Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19
granted -
US 12233145
Ultra-violet absorbing compounds
granted -
US 12233042
Treatment of cutaneous disorders
granted -
US 12234461
Targeted non-viral DNA insertions
granted -
US 12233073
Skin care formulations and skin cancer treatment
granted -
US 12233132
Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
granted -
US 12234263
Influenza vaccines
granted -
US 12234294
Pharmaceutical composition of a humanized anti-CD40 antibody
granted -
US 12234288
Immunogenic arginase 2 polypeptides
granted -
US 12234516
Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof
granted -
US 12234474
Method to prevent the myelin abnormalites associated with arginase deficiency
granted -
US 12234260
Virus-like nanoparticles for oral delivery
granted -
US 12233241
Methods and systems to validate physiologic waveform reliability and uses thereof
granted -
US 12233166
Extended release compositions comprising pyridostigmine
granted -
US 12234480
Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
granted -
WO 2025040080
TRAITEMENT DU CANCER DE L'OESOPHAGE PAR ANTI-LAG3, ANTI-PD-1 ET CHIMIOTHÉRAPIE
granted -
US 2025064917
HVT AIV VECTORS AND USES THEREOF
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
WO 2025043148
INHIBITEURS DE PROTÉINE DE LIAISON À L'ÉMOPAMIL ET LEURS UTILISATIONS
granted -
WO 2025041076
COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE CDK
granted -
US 12239717
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12240914
Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof
granted -
US 12241087
Compositions and methods for differentiating stem cells into NK cells
granted -
US 12240902
Anti-TREM2 antibodies and methods of use thereof
granted -
US 12240846
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 12240831
Pyridazinone compounds and uses thereof
granted -
US 12239687
Sustained release formulations using non-aqueous membrane emulsification
granted -
US 12241067
Compounds and methods for reducing LRRK2 expression
granted -
US 12240907
N-terminal scFv multispecific binding molecules
granted -
US 12240816
Deuterated compounds and uses thereof
granted -
US 12239709
Biodegradable lipids for the delivery of active agents
granted -
US 12239694
Methods and compositions for improved cognition
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.